ADVERTISEMENT
Epidemiological, clinical and therapeutic profile of gastric cancer
Gastric cancer is common in men with 65% of patients being male. It is the second digestive cancer after colorectal cancer and the second cause of death by digestive cancer, the incidence increases with age. The prognosis is poor, surgical treatment remains the treatment of choice. Chemotherapy is indicated in operable forms as adjuvant treatment, but especially in locally advanced or metastatic forms.
This is a retrospective study conducted in the Oncology Department of the military hospital of Oran from January 2020 to December 2022, including 30 patients with gastric cancer treated with surgery and/or complementary or palliative chemotherapy.
Of the 30 patients, 21 were men and 09 were women (sex ratio: 2.3), the median age was 62 years with extremes (22-80 years), 47% of the patients were in WHO1, 30% in WHO2, 7% in WHO3 and 16% in WHO4. 75% were stage IV, 7% stage III, 3% stage IIb, 20% benefited from gastrectomy and complementary chemotherapy, 57% from chemotherapy alone, and 20% were non-operated and received symptomatic treatment.
Stomach cancer is common and of late diagnosisin our context. Surgical treatment of early forms and perioperative chemotherapy could improve the prognosis of these cancers, but he has poor prognosis with limited treatment due to late diagnosis and consequent alteration of the general condition.
The authors.
Has not received any funding.
All authors have declared no conflicts of interest.
